Rhythm Biosciences: Strategic Growth and Investment Outlook.

Rhythm Biosciences (ASX: RHY) is positioning itself as a key player in early cancer detection through its innovative diagnostic solutions. With a share price of AU$0.105 and a market capitalisation of AU$29.83 million, the company focuses on delivering affordable, high-quality tests such as ColoSTAT for colorectal cancer and the geneType platform for risk assessment across various cancers. Its diversified product pipeline addresses a significant global market exceeding 500 million individuals, spanning regions including Australia, the USA, Europe, and Asia.

The company is preparing for major growth milestones, including the clinical validation of ColoSTAT and strategic partnerships for geneType in 2025. Upcoming product expansions, such as lung cancer screening assays, further strengthen its portfolio. A recent capital raise of approximately AU$3.75 million will support development and commercialisation. With a strong pipeline and global scalability, Rhythm offers investors exposure to substantial long-term healthcare opportunities.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com